corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items where at least one author is a Healthy Skepticism member

Page 2 of 3 pages  < 1 2 3 > 

HSL6060
Healy D, Herxheimer A, Menkes D.
Antidepressants and Violence: Problems at the Interface of Medicine and Law
PLoS 2006 Sep 13
http://medicine.plosjournals.org/perlserv?request=get-document&doi=10.1371/journal.pmed.0030372

HSL6069
Korczak V.
What's wrong with pushing pills?
New Matilda 2006 Sep 8
http://www.google.com.au/url?sa=t&rct=j&q=a%20consumer%20complaint%20about%20pharmaceutical%20advertising%20reveals%20the%20%0Ainadequacy%20of%20the%20medicines%20australia%20(ma)%20code%20of%20conduct%20that%20%0Aregulates%20the%20marketing%20of%20drugs%20in%20australia.%20while%20direct%20to%20consumer%20%0Aadvertising%20is%20prohibited%20in%20australia%2C%20companies%20are%20employing%20%0Aincreasingly%20novel%20marketing%20techniques%20to%20reach%20consumers%20and%20are%20%0Asucceeding.%20the%20code%20needs%20to%20be%20strengthened%2C%20starting%20with%20higher%20%0Asanctions%20and%20more%20effective%20monitoring.%20failing%20this%2C%20new%20legislation%20%0Aneeds%20to%20be%20introduced%20and%20enforced%20through%20an%20appropriate%20regulator.&source=web&cd=1&ved=0CCEQFjAA&url=http%3A%2F%2Fwww.choice.com.au%2F~%2Fmedia%2Ffiles%2Fconsumer%2520action%2Fhealth%2Fdrug%2520advertising%2Ff126086.ashx&ei=iVoWT8S8DaahiAfm87jhAw&usg=AFQjCNGzwV8sHo7LOXv6B-ZcHnQNDvtKzA&sig2=RlCrwOAn2628tPWhpR1DeQ&cad=rja

HSL5788
Harvey K.
Drug companies' free lunches have expensive side-effects
New Matilda 2006 Aug 4
http://cpd.org.au/2006/08/drug-companies-free-lunches-have-expensive-side-effects/

HSL5589
Mansfield PR.
Another way to tame the monster
BMJ 2006 Jul 22;333:(7560):202
http://bmj.bmjjournals.com/cgi/content/short/333/7560/202-a?etoc%3e

HSL5574
Mansfield PR.
A more comprehensive alternative
PLoS Med 2006 Jul 18;3:(7):306
http://medicine.plosjournals.org/perlserv/?request=read-response&doi=10.1371/journal.pmed.0030306

HSL5501
Lexchin J.
Risks and benefits of the profit motive in the pharmaceutical industry
Agora Vox 2006 Jul 11
http://www.agoravox.com/article.php3?id_article=4957

HSL5464
Mansfield PR.
Rapid responses: A more comprehensive and achievable alternative
BMJ 2006 Jul 8;333:
http://bmj.bmjjournals.com/cgi/eletters/333/7558/0-f

HSL8522
Lexchin J, Williams R, Marion J.
Rebuttal: are drugs too expensive in Canada?
Can Fam Physician 2006 Jul;52:841-2,:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16893142

HSL5267
Fugh-Berman A, Alladin K, Chow J.
Advertising in Medical Journals: Should Current Practices Change?
PLoS Med 2006 Jun 27;3:(6):e130
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0030130

HSL5194
Lexchin J, Light DW.
Commercial influence and the content of medical journals.
BMJ 2006 Jun 17;332:(7555):1444-7
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1444?etoc

HSL4961
Mira AJ, Isely W, McDonnell M, Huch KM, Whittle HM, Nugent TJ, Lack DZ
Readers' Responses to "Physicians on the Take"
MedGenMed 2006 May 12;
http://www.medscape.com/viewarticle/531612?src=mp

HSL4542
McConnell M.
An open letter to Healthy Skepticism:
2006 May 3

HSL5769
Lexchin J.
Are drugs too expensive in Canada? Yes
Can Fam Physician. 2006 May 01;52:573-6, 578-81
http://web.archive.org/web/20081201092146/http://www.cfpc.ca/cfp/2006/May/vol52-may-debates-1.asp?

HSL9984
Lexchin J.
Who Should Own the Presses?
Israeli Journal of Emergency Medicine 2006 May;6:(2):3-5
http://www.isrjem.org/Lexchin.Editorial.proof2.pdf

HSL4978
Biron P, Mintzes B, Lexchin J.
Questions about Adderall XR.
CMAJ 2006 Apr 25;174:(9):1303-4
http://www.cmaj.ca/cgi/content/full/174/9/1303-a

HSL3925
A Collection of Articles on Disease Mongering
PLoS Medicine ( Public Library of Science) 2006 Apr 11
http://collections.plos.org/diseasemongering-2006.php

HSL3926
Henry D, Moynihan R.
Inaugural Conference on Disease-Mongering
diseasemongering.org 2006 Apr 11
http://www.diseasemongering.org/

HSL4981
Lexchin J.
Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
CMAJ 2006 Apr 11;174:(8):1120-1
http://www.cmaj.ca/cgi/content/full/174/8/1120

HSL5466
Mansfield PR.
Universal Hepatitis-B Vaccination in India: A Questionable Strategy
BMJ 2006 Apr 7;302:
http://bmj.bmjjournals.com/cgi/eletters/332/7545/804

HSL8521
Roughead EE, Lexchin J.
Adverse drug events: counting is not enough, action is needed.
Med J Aust 2006 Apr 3;184:(7):315-6
http://www.mja.com.au/public/issues/184_07_030406/rou10066_fm.html

HSL3920
Jureidini J.
Systematic checks can avert crisis from adverse drug reactions
The Australian Newspaper 2006 Apr 1
http://www.theaustralian.news.com.au/common/story_page/0,5744,18666410%255E23289,00.html

HSL5465
Mansfield PR, Phadke A, Kale A.
Blanket hepatitis B vaccination is questionable in India
BMJ 2006 Apr 1;332:(7547):976

HSL7875
Lexchin J.
Bigger and Better: How Pfizer Redefined Erectile Dysfunction
PLoS Med 2006 Apr;3:(4):
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030132

HSL3909
Almasi E, Stafford R, Kravitz RL, Mansfield PR.
What Are the Public Health Effects of Direct-to-Consumer Drug Advertising?
PLoS Medicine 2006 Mar 28;3:(3):e145
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030145

HSL5162
Lexchin J .
Withdrawals of drugs for safety reasons: How do regulators decide if they are too unsafe?
Reaction Bulletin 2006 Feb 1;236:

HSL8519
Lexchin J.
Is there still a role for spontaneous reporting of adverse drug reactions?
CMAJ 2006 Jan 17;174:(2):191-2
http://www.cmaj.ca/cgi/content/full/174/2/191

HSL6382
Tonkin AL, Taverner D, Latte J, Doecke C.
The Effect of an Interactive Tutorial on the Prescribing Performance of Senior Medical Students
Med Educ. 2006;

HSL6423
Mansfield PR, Lexchin J, Wen LS, Grandori L, McCoy CP, Hoffman JR, Ramos J, Jureidini JN.
Educating Health Professionals about Drug and Device Promotion: Advocates' Recommendations
PLoS Med 2006;3:(11):e451
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371%2Fjournal.pmed.0030451

HSL6424
Mansfield P.
Industry-Sponsored Research: A More Comprehensive Alternative.
PLoS Med 2006;3:(10):e463
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030463

HSL8278
Cohen JC, Illingworth P, Schuklenk U, Eds .
The Power of Pills
London: Pluto Press 2006
http://www.plutobooks.com/cgi-local/nplutobrows.pl?chkisbn=9780745324029&main=&second=&third=&foo=../ssi/ssfooter.ssi

HSL8518
Jureidini J, Tonkin A.
Overuse of antidepressant drugs for the treatment of depression.
CNS Drugs 2006;20:(8):623-32
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16863268&query_hl=29&itool=pubmed_DocSum

HSL8523
Jureidini JN, Mansfield PR.
The scope of the problem of the relationship between drug companies and doctors
Maitra B, Timimi S. Critical Voices in Child and Adolescent Mental Health London: Free Association Books 2006
http://www.fabooks.com/book.php?id=434

HSL11870
Light D.
Basic research funds to discover important new drugs: who contributes how much?
Burke MA, De Francisco A. Monitoring Financial Flows for Health Research 2005: Behind the Global Numbers Geneva: Global Forum for Health Research 2006
http://web.archive.org/web/20090610012035/http://www.bioethics.upenn.edu/People/?last=Light&first=Donald

HSL2985
Harvey K.
Submission to ACCC re: Application A90994-6 by Medicines Australia re revised Code of Conduct [15th Ed]
Medreach ( www.medreach.com.au ) 2005 Dec 14
http://web.archive.org/web/20060202114946/http://www.accc.gov.au/content/index.phtml/itemId/716327

HSL3491
Norris P, Herxheimer A, Lexchin J, Mansfield P.
Drug Promotion: What we know, what we have yet to learn.
Geneva: World Health Organisation and Health Action International 2005 Dec
http://apps.who.int/medicinedocs/en/d/Js8109e/

HSL2693
Light D, Lexchin J.
US drug prices not Canada's fault, study says
York University 2005 Oct 22
http://www.yorku.ca/mediar/archive/Release.asp?Release=966

HSL9985
Light DW, Lexchin J.
Foreign free riders and the high price of US medicines.
BMJ 2005 Oct 22;331:(7522):958-60
http://www.bmj.com/cgi/content/full/331/7522/958

HSL2623
Goodman, B
Pictures at an Exhibition: The 2005 American Academy of Family Practice Annual Meeting, San Francisco, California
No Free Lunch 2005 Oct 2
http://nofreelunch.org/news.htm

HSL9986
Lexchin J.
Commentary: Nesiritide and Lessons Unlearned
Israeli Journal of Emergency Medicine 2005 Oct;5:(4):69-72
http://www.isrjem.org/NesiritideOct05.pdf

HSL5467
Mansfield PR.
Response to Jeffrey Mann: Clinical trials never produce certainty
BMJ 2005 Sep 16;331:
http://bmj.bmjjournals.com/cgi/eletters/331/7516/528

HSL5468
Mansfield PR.
Celecoxib causes excess cardiovascular events and illustrates the folly of allowing drug sellers too much power.
BMJ 2005 Sep 10;331:
http://bmj.bmjjournals.com/cgi/eletters/331/7516/528

HSL3487
Mansfield PR.
Banning all drug promotion is the best option pending major reforms.
J Bioethical Inquiry 2005;2:(2):16-22

HSL5469
Mansfield PR, Tonkin AL, Jureidini JN.
Fluoxetine for depressed adolescents: harms likely to exceed benefits
BMJ 2005 May 28;330:
http://bmj.bmjjournals.com/cgi/eletters/330/7493/730-b

HSL1937
Harvey KJ, Vitry AI., Aroni R, Ballenden N, Faggotter R.
Pharmaceutical advertisements in prescribing software: an analysis
MJA 2005 Jul 18;183:(2):75-79
http://www.mja.com.au/public/issues/183_02_180705/har10263_fm.html

HSL1659
Mansfield PR.
Response to Pfizer
BMJ 2005 Jun 27;
http://bmj.bmjjournals.com/cgi/eletters/328/7444/879#110681

HSL5846
Toop L, Richards D, Dowell T.
Response to Maubach and Hoek's paper on GP attitudes to DTCA
N Z Med J. 2005 Jun 24;118:(1217):U1543

HSL1688
Stocks N, Allan J, Mansfield PR.
Management of hyperlipidaemia.
Aust Fam Physician 2005 Jun;34:(6):447-53
http://www.racgp.org.au/document.asp?id=17049

HSL8036
Mintzes B, Barer M, Lexchin J, Bassett KL.
Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.
Res Social Adm Pharm 2005 Jun;1:(2):310-30

HSL1498
Dinant G-J, Mansfield P.
Van zoete koek naar gezonde scepsis: De houding van huisartsen tegenover geneesmiddelenreclame
Huisarts Wet 2005 May 2;48:(6):304-307
http://vb23.bsl.nl/frontend/framesets/index_henw.asp?custom_product_id=0018-7070&product_id={4BB053D4-D6F3-42A7-84AD-AF62B178743F}

HSL5590
Shann F.
Non-specific effects of vaccination: vaccines have non-specific (heterologous) effects.
BMJ 2005 Apr 9;330:(7495):844
http://bmj.bmjjournals.com/cgi/content/full/330/7495/844

HSL637
Mansfield PR, Vitry A.
Rofecoxib withdrawal.
Australian Prescriber 2005 Apr;28:(2):30
http://www.australianprescriber.com/index.php?content=/magazines/vol28no2/28_33_letters.htm

HSL1030
Lexchin J.
Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
CMAJ 2005 Mar 15;172:(6):765-7
http://www.cmaj.ca/cgi/content/full/172/6/765

HSL987
Raven M, Rogers W, Jureidini J.
Partnerships between academic psychiatry and the pharmaceutical industry.
Australas Psychiatry 2005 Mar;13:(1):83-4
http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=1039-8562&date=2005&volume=13&issue=1&spage=83

HSL1608
Mansfield PR.
Beliefs and plans of GP registrars before and after a 90 minute talk about drug promotion
Unpublished 2005 Feb 25;

HSL240
Mansfield PR, Vitry AI, Wright JM.
Withdraw all COX-2-selective drugs.
Med J Aust 2005 Feb 21;182:(4):197
http://www.mja.com.au/public/issues/182_04_210205/matters_arising_210205_fm-1.html

HSL1029
Lexchin J.
Prescribing errors
CMAJ 2005 Jan 18;172:(2):
http://www.cmaj.ca/cgi/content/full/172/2/229

HSL1031
Lexchin J, Cassels A.
Does the C in CME stand for "Continuing" or "Commercial"?
CMAJ 2005 Jan 18;172:(2):160-2
http://www.cmaj.ca/cgi/content/full/172/2/160-a

HSL2033
Mansfield PR, Mintzes B, Richards D, Toop L.
Direct to consumer advertising.
BMJ 2005 Jan 1;330:(7481):5-6
http://bmj.bmjjournals.com/cgi/content/full/330/7481/5

HSL1034
Lexchin JR.
Implications of pharmaceutical industry funding on clinical research.
Ann Pharmacother 2005 Jan;39:(1):194-7
http://www.theannals.com/cgi/content/full/39/1/194

HSL5421
Jureidini JN, Tonkin A.
Suicide and antidepressants in children (editorial)
Australian Prescriber 2005;28:110-1
http://www.australianprescriber.com/magazine/28/5/110/1/

HSL5579
Mansfield PR, Raven MK, Jureidini JN.
Depressed youth, suicidality and antidepressants
MJA 2005;183:(5):275-276
http://www.mja.com.au/public/issues/183_05_050905/letters_050905_fm-1.html

HSL9987
Lexchin J.
Intellectual propety rights and the Canadian pharmaceutical marketplace: Where do we go from here?
International Journal of Health Services 2005;35:(2):237 - 256
http://baywood.metapress.com/(iurdbb45zrns2y55w4i3yn45)/app/home/contribution.asp?referrer=parent&backto=issue,2,13;journal,9,146;linkingpublicationresults,1:300313,1

HSL9988
Mintzes B, Lexchin J.
Do higher drug costs lead to better health?
Can J Clin Pharmacol 2005 Win;12:(1):e22-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16055941&query_hl=8&itool=pubmed_DocSum

HSL1
Mansfield P.
Accepting what we can learn from advertising's mirror of desire.
BMJ 2004 Dec 18;329:(7480):1487-8
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=15604193

HSL355
Jureidini J, Tonkin A, Mansfield PR.
TADS study raises concerns.
BMJ 2004 Dec 4;329:(7478):1343-4
http://bmj.bmjjournals.com/cgi/content/full/329/7478/1343-d

HSL353
Light DW, Lexchin J.
Will lower drug prices jeopardize drug research? A policy fact sheet
Am J Bioeth 2004 Winter;4:(1):1-4
http://bioethics.net/journal/j_articles.php?aid=61

HSL4447
Mansfield PR.
Safety Query.
Australian Doctor Weekly 2004 Nov 17

HSL285
Allen K, Mansfield P.
Changing attitudes to 'the change'.
Aust Fam Physician 2004 Nov;33:(11):939-40
http://www.racgp.org.au/document.asp?id=15004

HSL354
Mansfield PR, Henry D.
Misleading drug promotion--no sign of improvements.
Pharmacoepidemiol Drug Saf 2004 Nov;13:(11):797-9
http://www3.interscience.wiley.com/cgi-bin/abstract/107632790/ABSTRACT

HSL5472
Mansfield PR.
Reform of incentives would help reduce harm from drug promotion
BMJ 2004 Oct 30;329:
http://bmj.bmjjournals.com/cgi/eletters/329/7473/998

HSL5473
Mansfield PR.
Reply to Stephen Black and Nicholas DeMartinis
2004 Oct 15;329:
http://bmj.bmjjournals.com/cgi/eletters/329/7468/748

HSL365
Mansfield PR.
Banned drug's world of faceless victims
The Independent Weekly (Adelaide) 2004 Oct 10-16

HSL5474
Mansfield PR, Tonkin AL, Jureidini JN.
Antidepressants do less good than harm for children and adolescents
BMJ 2004 Oct 8;329:
http://bmj.bmjjournals.com/cgi/eletters/329/7470/809

HSL1607
Mansfield PR.
A 5 minute read re drug promotion: RCT
Poster presented at 8th World Congress on Clinical Pharmacology & Therapeutics (CPT2004) Brisbane 2004 Aug 1-6;

HSL1161
Toop L, Richards D.
Physicians' negative views of direct-to-consumer advertising (DTCA): the international evidence grows.
N Z Med J 2004 Jun 4;117:(1195):U905

HSL5475
Mansfield PR.
Clarification and Update for AdWatch on Nexium dialogue
BMJ 2004 Apr 30;328:
http://bmj.bmjjournals.com/cgi/eletters/328/7447/1035-a

HSL151
Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN.
The ethics of pharmaceutical industry relationships with medical students.
Med J Aust 2004 Apr 19;180:(8):411-4
http://www.mja.com.au/public/issues/180_08_190404/rog10715_fm.html

HSL152
Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL.
Efficacy and safety of antidepressants for children and adolescents.
BMJ 2004 Apr 10;328:(7444):879-83
http://bmj.com/cgi/content/full/328/7444/879

HSL1417
Timimi S, Moncrieff J, Jureidini J, Leo J, Cohen D, Whitfield C, Double D, Bindman J, Andrews H, Asen E, Bracken P, Duncan B, Dunlap M, Albert G, Green M, Greening T, Hill J, Huws R, Karon B, Kean B, McCubbin M, Miatra B, Mosher L, Parry S, DuBose Ravenel
A critique of the international consensus statement on ADHD.
Clin Child Fam Psychol Rev 2004 Mar;7:(1):59-63

HSL4474
Ong A, Mansfield PR.
Controversies: Should free drug samples be banned?
Australian Doctor Weekly 2004 Feb 6

HSL356
Svensson S, Mansfield PR.
Escitalopram: superior to citalopram or a chiral chimera?
Psychother Psychosom 2004 Jan-Feb;73:(1):10-6
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=PPS2004073001010

HSL357
Mansfield P, Henry D, Tonkin A.
Single-enantiomer drugs: elegant science, disappointing effects.
Clin Pharmacokinet 2004;43:(5):287-90
http://www.ingentaconnect.com/content/adis/cpk/2004/00000043/00000005/art00002

HSL11251
Medawar C, Herxheimer A.
A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine
The International Journal of Risk and Safety in Medicine 2004;16:(1):5-19
http://iospress.metapress.com/app/home/contribution.asp?referrer=parent&backto=issue,3,8;journal,12,26;linkingpublicationresults,1:103162,1;

HSL1189
Mansfield PR.
Healthy Skepticism's new AdWatch: understanding drug promotion.
Med J Aust 2003 Dec 1-15;179:(11-12):644-5
http://www.mja.com.au/public/issues/179_11_011203/man10667_fm.html

HSL858
Jureidini J, Mansfield P, Menkes D.
The statin wars.
Lancet 2003 Nov 29;362:(9398):1855

HSL859
Katz D, Mansfield P, Goodman R, Tiefer L, Merz J.
Psychological aspects of gifts from drug companies.
JAMA 2003 Nov 12;290:(18):2404-5
http://jama.ama-assn.org/cgi/content/full/290/18/2404-b

HSL4476
Carter H, Mansfield P.
Eye on ads.
Australian Doctor Weekly 2003 Nov 5

HSL13369
Moncrieff J, Double D.
Double blind random bluff.
Ment Health Today 2003 Nov;:24-6:
http://www.ncbi.nlm.nih.gov/pubmed/14689600

HSL422
Mansfield PR.
Healthy scepticism.
Aust Fam Physician 2003 Oct;32:(10):777

HSL284
Mansfield PR, Mintzes B.
Direct-to-consumer advertising is more profitable if it is misleading.
N Z Med J 2003 Sep 26;116:(1182):U610
http://www.nzma.org.nz/journal/116-1182/610/

HSL1913
Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, Evans RG, Pan R, Marion SA.
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
CMAJ. 2003 Sep 2;169:(5):405-12
http://www.cmaj.ca/cgi/content/full/169/5/405

HSL5477
Mansfield PR.
Drug marketing deserves recognition
BMJ 2003 Aug 28;327:
http://bmj.bmjjournals.com/cgi/eletters/327/7413/468-d

HSL5847
Toop L, Richards D, Saunders B.
New Zealand deserves better. Direct-to-consumer advertising (DTCA) of prescription medicines in New Zealand: for health or for profit?
N Z Med J. 2003 Aug 22;116:(1180):U556

HSL4479
Mansfield PR.
Gifts must go
Australian Doctor Weekly 2003 Aug 21

HSL860
Jureidini J, Mansfield P.
The journal and drug advertising.
Aust N Z J Psychiatry 2003 Aug;37:(4):495

HSL4481
Mansfield PR, Mak HK.
Drug reps: friend or foe?
Australian Doctor Weekly 2003 Jun 24

HSL423
Mansfield PR.
Bribes for doctors: a gift for bioethicists?
Am J Bioeth 2003 Summer;3:(3):47-8

HSL1213
Fugh-Berman A.
"Bust enhancing" herbal products.
Obstet Gynecol 2003 Jun;101:(6):1345-9
http://www.greenjournal.org/cgi/content/full/101/6/1345

HSL1193
Lexchin J, Bero LA, Djulbegovic B, Clark O.
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
BMJ 2003 May 31;326:(7400):1167-70
http://bmj.bmjjournals.com/cgi/content/full/326/7400/1167

HSL5478
Mansfield PR.
Free offer for all BMJ readers from Healthy Skepticism
BMJ 2003 May 30;326:
http://bmj.bmjjournals.com/cgi/eletters/326/7400/1205

Page 2 of 3 pages  < 1 2 3 > 

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.